Evofem Biosciences, Inc. (EVFM)

NASDAQ: EVFM · IEX Real-Time Price · USD
0.981
-0.089 (-8.36%)
At close: Jun 29, 2022 4:00 PM
0.910
-0.071 (-7.200%)
After-hours: Jun 29, 2022 6:02 PM EDT
-8.36%
Market Cap 34.69M
Revenue (ttm) 11.39M
Net Income (ttm) -192.06M
Shares Out 35.38M
EPS (ttm) -19.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date May 6, 2022
Volume 94,720,511
Open 0.935
Previous Close 1.070
Day's Range 0.798 - 1.050
52-Week Range 0.275 - 17.700
Beta -0.13
Analysts Buy
Price Target 22.54 (+2,198.6%)
Earnings Date Aug 10, 2022

About EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California. [Read more...]

Industry Pharmaceuticals
CEO Saundra Pelletier
Employees 119
Stock Exchange NASDAQ
Ticker Symbol EVFM
Full Company Profile

Financial Performance

In 2021, EVFM's revenue was $8.24 million, an increase of 1,748.43% compared to the previous year's $446,000. Losses were -$205.19 million, 44.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for EVFM stock is "Buy." The 12-month stock price forecast is 22.54, which is an increase of 2,198.59% from the latest price.

Price Target
$22.54
(2,198.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Evofem Biosciences (EVFM) Stock Remains in Spotlight With Contraception Access Deal

Evofem Biosciences has already announced a strategic partnership. Here's why this new deal is great news for EVFM stock.

What to Know About Buying Penny Stocks on June 28th

Here's what you need to know about buying penny stocks on June 28th The post What to Know About Buying Penny Stocks on June 28th  appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols: AGRXFEMY

Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®

Agreement Significantly Expands Access to Phexxi® for Millions of Women Seeking an FDA-Approved, Hormone-Free, On-Demand Option to Prevent Pregnancy Long-term Contract Adds to Growing List of Agreements...

EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision

Evofem Biosciences is in the spotlight following the overturning of Roe v. Wade. Here's why EVFM stock is a name to watch.

Birth-control drugmaker Evofem Biosciences has spiked 240% since the Supreme Court's decision to overturn Roe vs. Wade

Birth control drugmaker Evofem has attracted attention from investors amidst the setback for women's reproductive health.

Evofem's stock is still soaring after Friday's Supreme Court decision

Shares of Evofem Biosciences Inc. EVFM, +155.45% soared 164.6% in trading on Monday in a rally that began Friday when the Supreme Court decision striking down Roe v. Wade was announced.

Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: AFIBAGRXCYBNHILS

What to Know About Buying Penny Stocks on June 27th

Here's what you need to know about trading penny stocks on June 27th The post What to Know About Buying Penny Stocks on June 27th appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols: CPSREAL

Evofem's stock jumps 30% after Supreme Court decision on Roe v. Wade

Shares of Evofem Biosciences Inc. EVFM, +26.95% soared 30.6% in trading on Friday, hours after the Supreme Court decision striking down Roe v. Wade was announced.

Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial ...

Throughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc Analysis SAN DIEGO , June 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: ...

Traders News Source Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier

NEW YORK, NY / ACCESSWIRE / June 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a n...

US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years

SAN DIEGO , June 2, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that the U.S. Food and Drug Administration (FDA) has formally extended the shelf life of Phexxi®...

Why Evofem Biosciences Shares Are Getting Hammered Today

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering. Evofem says the company intends to u...

Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering

SAN DIEGO , May 20, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its...

Evofem Biosciences Announces Proposed Public Offering

SAN DIEGO , May 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase...

Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for...

SAN DIEGO , May 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has selected Bora Pharmaceuticals Services Inc. (Bora) Canada as Evofem's new contract manufacturing ...

Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical T...

5.8% of Women in the AMPOWER Trial Experienced an On-Study Urinary Tract Infection Compared to 11% in the General Population The Post hoc Analysis will be Presented at the 2022 American College of Obste...

Evofem Biosciences Announces 1-for-15 Reverse Stock Split

SAN DIEGO , May 5, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) (the "Company") today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of...

Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

-- Double digit growth in net revenues over Q4 2021 -- -- Reduced selling and marketing costs 49% and total operating expense 19% vs. Q4 2021 -- -- Decreased loss from operations for the third consecuti...

Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services

Evofem Anticipates Greater Numbers of Phexxi® (lactic acid, citric acid, potassium bitartrate) Prescriptions Filled as a Result of VitaCare Agreement New Agreement Provides More Efficient Patient Follow...

Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologist...

SAN DIEGO , April 26, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obste...

Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022

-- Conference Call Scheduled for 4:30 p.m. ET – SAN DIEGO , April 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results a...

Evofem Announces Karina Fedasz as Company's New Head of Business Development

Fedasz will Focus on Opening New Markets for Evofem's First - and Only – in-Class Contraceptive, Phexxi® (lactic acid, citric acid, and potassium bitartrate) SAN DIEGO, April 11, 2022 /PRNewswire/ -- Ev...

Nasdaq Accepts Evofem Plan to Regain Listing Compliance

Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of Evofem Common Stock before May 4, 2022, with Compliance by May 20, 2022 SAN DIEGO , April 7, 2022 /PRNewswire/...

Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Manage...

Phase 2B/3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in Chlamydia Trachomatis (chlamydia) and a 78 Percent Risk Reduction in Neisseria Gonorrhoeae (gonorrhe...